Crispr Therapeutics (CRSP) and Sirius Therapeutics announced a strategic partnership to develop and commercialize siRNA therapies. Under the terms of the agreement, Crispr Therapeutics will make an upfront payment of $25M in cash and $70M in equity to Sirius Therapeutics. The companies will jointly develop SRSD107 under a 50-50 cost and profit-sharing structure. Crispr Therapeutics will lead commercialization in the U.S., while Sirius will be responsible for commercialization in Greater China. Additionally, Crispr Therapeutics will have the option to nominate up to two siRNA targets for research and development. For each target, Crispr Therapeutics will fund research and retain opt-in rights to lead clinical development and commercialization. Sirius will be eligible to receive milestone payments, as well as tiered royalties ranging from high single to low-double digits.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Here’s Why Cathie Wood Walked Away from PLTR and ACHR Stocks
- Illinois Tool Works, Wynn Resorts, Agree Realty, Crispr Therapeutics, Super Micro Computer: Trending by Analysts
- Crispr Therapeutics price target lowered to $42 from $56 at Barclays
- Promising Developments and Pipeline Expansion at Crispr Therapeutics AG Support Buy Rating
- CRISPR Therapeutics Reports Q1 2025 Progress and Financials
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue